Buy MAZE right now: the stock is pulling back into a key support/pivot area while the broader trend remains bullish (SMA_5 > SMA_20 > SMA_200).
Options positioning is risk-on (put/call OI ratio < 1 and essentially no put volume), supporting near-term upside bias.
Wall Street remains broadly bullish with multiple recent target raises and initiations ahead of 2026 catalysts; today’s dip improves entry versus recent strength.
Not a “signal-driven strong buy” (no Intellectia AI Stock Picker / SwingMax signal), but the setup still favors an impatient buyer looking for near-term continuation off support.
Technical Analysis
Trend: Bullish structure with moving averages stacked positively (SMA_5 > SMA_20 > SMA_200), implying an uptrend despite today’s -4.75% drop.
Momentum: MACD histogram is positive (0.305) but contracting, suggesting upside momentum is slowing short-term (more consolidation/pullback risk than straight-line rally).
RSI: RSI_6 at ~60.6 (neutral-to-slightly bullish), not overbought—room for another push higher if buyers defend support.
Levels: Pivot 45.683 is the immediate battleground; price (~45.415) is slightly below pivot.
Support: S1 42.998 (next downside level if pivot fails), then S2 41.338.
Resistance: R1 48.368 then R2 50.028 (clear upside targets if price reclaims pivot and bounces).
Pattern-based odds (provided): 60% probability skew with projected gains of ~1.08% (1D), 3.43% (1W), 7.18% (1M), consistent with a buy-the-dip bias.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment/positioning: Open interest put-call ratio 0.63 is bullish (more calls positioned than puts).
Flow today: Option volume put-call ratio 0.0 (22 calls vs 0 puts) indicates traders are leaning upside intraday.
Volatility: 30D IV ~112.44 vs historical vol ~54.7; IV percentile 93.75 indicates options are pricing large moves.
Activity: Today’s volume (22) is elevated vs 30D average (~68.75% of avg noted) and open interest is meaningfully engaged (todays OI 1045; today vs OI avg 172.44), suggesting heightened interest into upcoming events.
Technical Summary
Sell
2
Buy
7
Positive Catalysts
and explicit enthusiasm for APOL1 kidney disease opportunity.
Neutral/Negative Catalysts
Insider transaction: SVP of Finance Amy Bachrodt exercised and sold 5,000 shares (~$227.6k) under a 10b5-1 plan (not necessarily bearish, but it is a sell).
Financial profile remains clinical-stage: revenue is currently zero and losses persist (limits fundamental support until clinical/financing milestones improve).
Near-term technical: MACD positive but contracting + today’s sharp down day increases the chance of a short consolidation before the next leg up.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: Dropped to 0 (-100% YoY), consistent with a pre-commercial/clinical-stage company.
Profitability: Net income improved to -$30.087M (up 1139.68% YoY improvement per dataset), indicating a materially smaller loss vs prior year.
EPS: Improved to -0.66 (up 1000% YoY improvement per dataset), also indicating loss narrowing.
Gross margin: 0 (down -100% YoY), consistent with no revenue.
Takeaway: improving loss profile quarter-over-quarter/year-over-year (per provided stats), but still an R&D-driven business where valuation will hinge on clinical execution and catalysts rather than near-term revenue growth.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Rating trend: Strongly positive. Recent initiations and reiterations are predominantly bullish (Buy/Overweight/Strong Buy).
Price target trend: Rising.
BTIG (2026-01-19): PT raised to $46 from $37 (Buy).
Guggenheim (2025-12-19): PT raised to $46 from $34 (Buy).
H.C. Wainwright (2025-12-03): PT raised to $60 from $50 (Buy).
Raymond James (2025-11-13): Initiated Strong Buy, PT $48.
Wall Street pros view (pros): Best-in-class potential for APOL1 inhibitor program, multiple 2026 catalysts, large stated peak sales opportunity.
Wall Street cons view (cons): Implied dependence on upcoming clinical readouts/execution (typical for clinical-stage biotech) and limited current fundamental revenue base.
Wall Street analysts forecast MAZE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MAZE is 51.33 USD with a low forecast of 42 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast MAZE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MAZE is 51.33 USD with a low forecast of 42 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 43.950
Low
42
Averages
51.33
High
60
Current: 43.950
Low
42
Averages
51.33
High
60
BTIG
Buy
maintain
$37 -> $46
AI Analysis
2026-01-19
Reason
BTIG
Price Target
$37 -> $46
AI Analysis
2026-01-19
maintain
Buy
Reason
BTIG raised the firm's price target on Maze Therapeutics (MAZE) to $46 from $37 and keeps a Buy rating on the shares. The firm believes the bar for success for Maze's upcoming HORIZON data in APOL1-mediated kidney disease is "notably below" what Vertex Pharmaceuticals' (VRTX) inaxaplin previously showed in a Phase 2 trial that only enrolled severe focal segmental glomerulosclerosis. HORIZON's broader patient population looks more representative of the actual market that both therapies are pursuing, the analyst tells investors in a research note. BTIG likes the risk/reward for Maze shares through the HORIZON data, even considering the stock's recent outperformance.
Guggenheim
Debjit Chattopadhyay
Buy
upgrade
$34 -> $46
2025-12-19
Reason
Guggenheim
Debjit Chattopadhyay
Price Target
$34 -> $46
2025-12-19
upgrade
Buy
Reason
Guggenheim analyst Debjit Chattopadhyay raised the firm's price target on Maze Therapeutics to $46 from $34 and keeps a Buy rating on the shares as part of a 2026 outlook note for the analyst's Biotechnology coverage.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MAZE
